Jasper Therapeutics (NASDAQ:JSPR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other brokerages also recently issued reports on JSPR. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. William Blair assumed coverage on Jasper Therapeutics in a research report on Wednesday, October 14th. They set an “outperform” rating on the stock. Piper Sandler initiated coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.33.

Jasper Therapeutics Stock Down 2.3%

NASDAQ:JSPR opened at $0.51 on Friday. The stock has a market cap of $16.91 million, a price-to-earnings ratio of -0.32 and a beta of 3.16. The company’s 50 day moving average price is $0.60 and its 200-day moving average price is $0.85. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $2.42.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, sell-side analysts anticipate that Jasper Therapeutics will post -0.94 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.